Par Drugs And Chemicals Limited has informed the Exchange regarding Outcome of Board Meeting held on May 08, 2025.
PAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The board approved audited standalone results for Q4 FY25 and full year FY25. Full-year revenue from operations grew ~5.6% to ₹10,097.35 lakh (vs ₹9,564.04 lakh), but profit after tax declined ~7.9% to ₹1,335.79 lakh (vs ₹1,450.10 lakh), with EPS at ₹10.86 (vs ₹11.78). Q4 FY25 showed a sharp sequential recovery, with PAT jumping to ₹165.10 lakh from ₹57.80 lakh in Q3 FY25. Other income surged to ₹215 lakh (vs ₹24 lakh), lifting total revenue to ₹10,312 lakh. The auditor issued an unmodified opinion but flagged a Key Audit Matter: during the year, the board approved a slump sale of the company's primary business unit, which contributed over 99% of revenue, while planning to enter clean energy, real estate, and capital markets. Cash from operations fell to ₹1,616 lakh, investments surged to ₹2,507 lakh, and total equity rose to ₹9,897 lakh.
Mixed near-term signals — full-year PAT slipped despite revenue growth, and the auditor's flagged slump sale of the core API unit (>99% of revenue) signals a major strategic pivot that fundamentally changes the company's business profile. Shareholders should watch closely for further disclosures on the slump sale and the new business verticals, as the transition will define future earnings.